<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04826445</url>
  </required_header>
  <id_info>
    <org_study_id>2019-A00965-52</org_study_id>
    <secondary_id>2019/2931</secondary_id>
    <nct_id>NCT04826445</nct_id>
  </id_info>
  <brief_title>USE OF 18FDG PET-CT TO PREDICT THE RESPONSE OF MANDIBULAR OSTEORADIONECROSIS TO THE PENTOCLO PROTOCOL WITH DOCUMENTED ANTIBIOTHERAPY</brief_title>
  <acronym>PENTOTEP</acronym>
  <official_title>USE OF 18FDG PET-CT TO PREDICT THE RESPONSE OF MANDIBULAR OSTEORADIONECROSIS TO THE PENTOCLO PROTOCOL WITH DOCUMENTED ANTIBIOTHERAPY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is created in order to refine and reduce the duration between the medical and&#xD;
      surgical therapeutic sequences (when the surgery is necessary) in these fragile patients&#xD;
      knowing that conventional radiological changes can only be observed with a delay comprised&#xD;
      between 3 and 6 months starting from observed clinical changes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 11, 2019</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>diagnosis performance of 18-FDG PET-CT</measure>
    <time_frame>up to 3 months</time_frame>
    <description>Evaluate the diagnosis performance of 18-FDG PET-CT with the criteria of Mandibular mean FDG uptake compared between the reference test and at 3 months: Î”SUVmean</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Mandibular Osteoradionecrosis</condition>
  <arm_group>
    <arm_group_label>Patients included in PENTOCLO protocol</arm_group_label>
    <description>We perform a prospective study with inclusions of all consecutive patients with osteoradionecrosis eligible for PENTOCLO.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Data collection</intervention_name>
    <description>Imaging collection</description>
    <arm_group_label>Patients included in PENTOCLO protocol</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with mandibular osteoradionecrosis treated in the PENTOCLO protocol&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with symptomatic osteoradionecrosis with a PENTOCLO protocol indication&#xD;
             (decided in a multi-disciplinary staff).&#xD;
&#xD;
          2. Patient should understand to any protocol-specific procedures performed. Patient who&#xD;
             did not object to participate after being informed of the study. Patient should be&#xD;
             able and willing to comply with study visits and procedures as per protocol.&#xD;
&#xD;
          3. Patients must be affiliated to a social security system or beneficiary of the same.&#xD;
&#xD;
          4. Patients must be over 18 years old (legal age).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Excluded forms of the disease: mandibular osteoradionecrosis complicated by mandibular&#xD;
             fracture and / or hyperalgesic (resistant to analgesic treatment of stage III).&#xD;
&#xD;
          2. Contraindications specific to the treatment under study (allergy to one of the&#xD;
             PENTOCLO treatments, contraindication to 18FDG PET-CT).&#xD;
&#xD;
          3. Associated pathology that contra-indicate on of the PENTOCLO treatment.&#xD;
&#xD;
          4. Pregnant woman, declaring likely to be pregnant or breastfeeding. Chilbearing age&#xD;
             women must declare not being pregnant and use effective contraception.&#xD;
&#xD;
          5. Impossibility to submit to the medical follow-up of the test for geographical, social&#xD;
             or psychological reasons.&#xD;
&#xD;
          6. Patient under guardianship or deprived of his liberty by a judicial or administrative&#xD;
             decision or unable to express its opposition to participating in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Aina DINNOO, MD</last_name>
    <phone>0142114211</phone>
    <phone_ext>+33</phone_ext>
    <email>ainia.dinnoo@gustaveroussy.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aina Dinnoo, MD</last_name>
      <phone>0142114211</phone>
      <phone_ext>+33</phone_ext>
      <email>aina.dinnoo@gustaveroussy.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 29, 2021</study_first_submitted>
  <study_first_submitted_qc>March 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2021</study_first_posted>
  <last_update_submitted>March 29, 2021</last_update_submitted>
  <last_update_submitted_qc>March 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoradionecrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

